Breaking News Instant updates and real-time market news.

BAC

Bank of America

$20.30

-0.56 (-2.68%)

, AAPL

Apple

$111.57

-0.22 (-0.20%)

08:55
11/29/16
11/29
08:55
11/29/16
08:55

Notable open interest changes for November 29th

Monday's total option volume of 13.8 million contracts resulted in net open interest growth of 2.48 million calls and 3.08 million puts. Bank of America (BAC), Apple (AAPL), Vale (VALE) and AstraZeneca (AZN) saw the greatest growth. Top five new positions opened include 28k Apple (AAPL) Jan-18 100 calls, 27k ArcelorMittal (MT) Dec-16 8 calls, 21k AstraZeneca (AZN) Jul-17 30 calls, 20k AstraZeneca (AZN) Jul-17 32.5 calls and 19k Dynavax (DVAX) Jan-17 18 calls.

BAC

Bank of America

$20.30

-0.56 (-2.68%)

AAPL

Apple

$111.57

-0.22 (-0.20%)

VALE

Vale

$9.10

0.68 (8.08%)

AZN

AstraZeneca

$26.73

-0.37 (-1.37%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 13

    Jan

  • 16

    Feb

BAC Bank of America
$20.30

-0.56 (-2.68%)

11/16/16
11/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sysco (SYY) downgraded to Neutral from Outperform at Credit Suisse with analyst Edward Kelly saying Sysco shares are up 50% over the last 18 months and now views risk/reward as balanced. 2. Teva (TEVA) downgraded to Hold from Buy at Jefferies, to Equal Weight from Overweight at Morgan Stanley, and to Neutral from Buy at BTIG. 3. Bank of America (BAC) Capital One (COF) downgraded to Neutral from Outperform at Baird while the firm downgraded Fifth Third (FITB) to Underperform from Neutral. 4. Zions Bancorp (ZION) downgraded to Equal Weight from Overweight at Morgan Stanley and to Market Perform from Outperform at Bernstein. 5. Yingli Green Energy (YGE) downgraded to Sell from Buy at Axiom while the firm downgraded SolarCity (SCTY) and JA Solar (JASO) to Sell from Hold. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/16
11/16/16
DOWNGRADE
Target $18

Neutral
Bank of America downgraded to Neutral from Outperform at Baird
As previously reported, Baird analyst David George downgraded Bank of America to Neutral from Buy as he believes the post-election rally has largely discounted the potential benefits of rising interest rates, lower taxes, and more aggressive capital return. George raised his price target to $18 from $17 on Bank of America shares.
11/16/16
BARD
11/16/16
DOWNGRADE
BARD
Neutral
Bank of America downgraded to Neutral from Outperform at Baird
11/29/16
KBWI
11/29/16
UPGRADE
Target $23
KBWI
Outperform
Bank of America upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Bank of America to Outperform citing expectations for improved operating and regulatory environments. The valuation remains reasonable despite the recent rally, Kleinhanzl tells investors in a research note. The analyst raised his price target for the shares to $23 from $17.50.
AAPL Apple
$111.57

-0.22 (-0.20%)

11/21/16
ADAM
11/21/16
NO CHANGE
Target $140
ADAM
Buy
Apple continues to dominate industry operating profits, says Canaccord
Canaccord analyst T. Michael Walkley said Apple captured a strong share of the premium-tier global smartphone market during Q3 and believes they will continue to extend their leading market share position. He noted Apple will continue to generate strong profit share despite iPhone sales moderating in North America over the past several weeks. Walkley expects steady iPhone 7 sales will help Apple return to growth in Q1 2017 and reiterated his Buy rating and $140 price target on the shares.
11/23/16
CLVD
11/23/16
NO CHANGE
CLVD
Neutral
Apple iPhone 7 supply remains constrained, says Cleveland Research
Cleveland Research said its near-term work remains encouraging on iPhone 7 demand and mix, with checks indicating that supply of iPhone 7 seems to be normalizing in most channels and tightness persists for the 7+. Discussions also suggest growing optimism for the next iPhone refresh, said the firm, which has a Neutral rating on Apple shares.
11/23/16
RSBL
11/23/16
NO CHANGE
RSBL
Apple trimming March quarter component order forecast, says Rosenblatt
Rosenblatt believes Apple has starting trimming its March quarter component order forecast following last week's December quarter production cut. The firm's analyst now expects orders to drop to 40M-43M units from 45M-46M, and believes March quarter's iPhone shipment consensus forecast of 52M-54M may be at risk.
11/29/16
UBSW
11/29/16
NO CHANGE
Target $127
UBSW
Buy
Apple procurement estimates suggest risk to next two quarters, says UBS
UBS analyst Steven Milunovich said Apple's procurement numbers for the December and March quarters have been revised downward, putting consensus estimates for the two quarters at risk. The analyst is leaving his estimates unchanged, but notes his view remains below consensus. He said many investors are looking to 2018, when high retention rates and an aging installed base could drive significant upgrades for the next iteration of the iPhone. Milunovich reiterated his Buy rating and $127 price target on Apple shares.
VALE Vale
$9.10

0.68 (8.08%)

09/12/16
JPMS
09/12/16
UPGRADE
Target $7
JPMS
Overweight
Vale upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Rodolfo Angele upgrade Vale to Overweight saying he now expects the company to post positive free cash flow in 2017 and beyond amid more supportive iron ore prices. The analyst raised his price target for the shares to $7 from $5.
09/21/16
LEHM
09/21/16
UPGRADE
Target $4
LEHM
Equal Weight
Vale upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Amos Fletcher upgraded Vale to Equal Weight with a $4 price target.
10/20/16
IBBA
10/20/16
UPGRADE
IBBA
Outperform
Vale upgraded to Outperform from Market Perform at Itau BBA
11/01/16
SBSH
11/01/16
UPGRADE
SBSH
Neutral
Vale upgraded to Neutral from Sell at Citi
AZN AstraZeneca
$26.73

-0.37 (-1.37%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.

TODAY'S FREE FLY STORIES

UBS

UBS

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Periodicals
UBS to start moving jobs in early 2018 ahead of Brexit, Telegraph reports »

UBS will begin shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

PHM

PulteGroup

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

RF

Regions Financial

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/22/18
01/22
09:18
01/22/18
09:18
Options
Overnight activity included 111 trades in SPX and 29 trades in VIX »

111 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RF

Regions Financial

09:17
01/22/18
01/22
09:17
01/22/18
09:17
Upgrade
Regions Financial rating change  »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

SDR

SandRidge Mississippian Trust II

09:16
01/22/18
01/22
09:16
01/22/18
09:16
Hot Stocks
SandRidge Mississippian Trust II receives NYSE notice on listing standards »

SandRidge Mississippian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:15
01/22/18
01/22
09:15
01/22/18
09:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

HAL

Halliburton

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
Halliburton says expects improved utilization to drive margin growth »

Sees boosting frack…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

09:14
01/22/18
01/22
09:14
01/22/18
09:14
Hot Stocks
FirstEnergy receives $2.5B equity investment »

FirstEnergy announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

DNKN

Dunkin' Brands

$64.56

-0.53 (-0.81%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Upgrade
Dunkin' Brands rating change  »

William Blair upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.85

-0.54 (-0.41%)

09:13
01/22/18
01/22
09:13
01/22/18
09:13
Recommendations
Visteon analyst commentary  »

Visteon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$65.75

0.65 (1.00%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Conference/Events
Mellanox management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

IOVA

Iovance Biotherapeutics

$10.70

1.075 (11.17%)

09:12
01/22/18
01/22
09:12
01/22/18
09:12
Recommendations
Iovance Biotherapeutics analyst commentary  »

Iovance Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:11
01/22/18
01/22
09:11
01/22/18
09:11
Hot Stocks
Halliburton says International business started to recover in 2H17 »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

09:10
01/22/18
01/22
09:10
01/22/18
09:10
General news
Treasury Option Action: doubly bullish positioning »

Treasury Option Action:…

GRA

W.R. Grace

$73.71

0.92 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Hot Stocks
W.R. Grace licenses UNIPOL PP process technology to Poland's Grupa Azoty »

W. R. Grace has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 02

    Mar

PRI

Primerica

$104.50

1.3 (1.26%)

09:09
01/22/18
01/22
09:09
01/22/18
09:09
Recommendations
Primerica analyst commentary  »

Primerica price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

ARCT

Arcturus Therapeutics

$9.15

-0.15 (-1.61%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Initiation
Arcturus Therapeutics initiated  »

Arcturus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$52.15

0.45 (0.87%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Upgrade
Meritage Homes rating change  »

Meritage Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

INSG

Inseego

$1.66

-0.01 (-0.60%)

09:08
01/22/18
01/22
09:08
01/22/18
09:08
Hot Stocks
Inseego says board adopts NOL rights plan »

Inseego Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

XRX

Xerox

$31.80

0.43 (1.37%)

09:06
01/22/18
01/22
09:06
01/22/18
09:06
Hot Stocks
Icahn, Deason call on Xerox to explore strategic alternatives, replace CEO »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$179.64

4.16 (2.37%)

09:05
01/22/18
01/22
09:05
01/22/18
09:05
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.